课题基金 / 基金详情

Serotonin Reuptake Inhibitors and 5-HT1A Receptors

Serotonin Reuptake Inhibitors and 5-HT1A Receptors
5-羟色胺再摄取抑制剂和 5-HT1A 受体
批准号:
7163798
负责人:
GEORGE BATTAGLIA
金额:
$32.45万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
已结题
起止时间:
1995-09-30 至 2009-05-31

项目摘要

项目成果

GEORGE BATTAGLIA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (Prozac/R) have revolutionized psychiatry. However, a major problem with SSRIs is a 2-3 week delay in therapeutic onset. Studies from the last funding period indicate that SSRIs produce a robust desensitization of hypothalamic post-synaptic serotonin lA (5-HT1A) receptors in rats. This desensitization has a gradual onset (7-14 days), corresponding with the 2-3 week delay in therapeutic effects of SSRIs. Hence, desensitization of post-synaptic 5-HTIA receptors could be a model of some of the therapeutic effects of SSRIs. The long delay in clinical improvement after the onset of SSRI treatment remains a fundamental problem that may be overcome by a more comprehensive understanding of the underlying basis for 5-HT1A receptor desensitization. Therefore this competitive renewal will focus on the mechanisms responsible for the homologous desensitization of post-synaptic hypothalamic 5-HTIA receptor systems during treatment of rats with SSRIs, The focus of this proposal is on the 5-HT1A receptor - Gz protein - mitogen-activated protein kinase (MAPK also known as ERK1/2) cascade. The MAP kinase cascade (Raf-MEK-ERK) is involved in many cellular processes including receptor desensitization. Our preliminary studies indicate that 5-HT1A-receptor activation produces a rapid phosphorylation of MAP kinase (ERK1/2) in the rat hypothalamic paraventricular nucleus. Our central hypothesis is that Gz protein-MAP kinase signaling mediates the desensitization of 5-HTIA receptors by SSRIs. Four specific aims are proposed: Specific Aim 1 will test the hypothesis that Gz proteins mediate the 5-HTIA receptor-mediated activation of MAP kinase signaling in the hypothalamus. Specific Aim 2 will test the hypothesis that reduced expression of Gz proteins mediates SSRI-induced desensitization of hypothalamic 5-HTIA receptors. Specific Aim 3 will test the hypothesis that MAP kinase signaling mediates the SSRI-induced desensitization of post-synaptic 5-HTIA receptors in the hypothalamus. Specific Aim 4 will identify the transcription factors (c-myc and Spl) that mediate fluoxetine-induced desensitization of 5-HTIA receptors. The proposed studies will provide an in-depth understanding of the regulation of post-synaptic 5-HTIA receptor signaling in vivo and will identify new targets for the treatment of mood disorders.
期刊论文(42)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1523/jneurosci.21-20-07919.2001
发表时间: 2001
期刊: The Journal of neuroscience : the official journal of the Society for Neuroscience
影响因子: --
作者: [Zhang,Y, D'Souza,D, Raap,DK, Garcia,F, Battaglia,G, Muma,NA, VandeKar,LD]
通讯作者: VandeKar,LD
Coadministration of 5-hydroxytryptamine(1A) antagonist WAY-100635 prevents fluoxetine-induced desensitization of postsynaptic 5-hydroxytryptamine(1A) receptors in hypothalamus.
5-羟色胺 (1A) 拮抗剂 WAY-100635 的共同给药可防止氟西汀诱导的下丘脑突触后 5-羟色胺 (1A) 受体脱敏。
DOI: --
发表时间: 2000
期刊: The Journal of pharmacology and experimental therapeutics
影响因子: --
作者: [Serres,F, Muma,NA, Raap,DK, Garcia,F, Battaglia,G, VandeKar,LD]
通讯作者: VandeKar,LD
Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist.
长期服用氟西汀会导致 5-HT1A 受体逐渐脱敏:下丘脑和中脑 Gi 和 G(o) 蛋白减少,以及对 5-HT1A 激动剂的神经内分泌反应减少。
DOI: --
发表时间: 1996
期刊: The Journal of pharmacology and experimental therapeutics.
影响因子: --
作者: [Li,Q, Muma,NA, vandeKar,LD]
通讯作者: vandeKar,LD
DOI: 10.1080/10253890802046281
发表时间: 2009-01
期刊: STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS
影响因子: 2.3
作者: [Grippo, Angela J., Johnson, Alan Kim]
通讯作者: Johnson, Alan Kim
19
    Time Course and Potentiation of Fluoxetin Action
    • 批准号:
      6692989
    • 项目类别:
    • 资助金额:
      $3.94万
    • 财政年份:
      2002
    • 负责人:
      GEORGE BATTAGLIA
    • 依托单位:
    TREATMENT OF COCAINE-INDUCED 5-HT DYSFUNCTION
    • 批准号:
      6700844
    • 项目类别:
    • 资助金额:
      $33.3万
    • 财政年份:
      2001
    • 负责人:
      GEORGE BATTAGLIA
    • 依托单位:
    TREATMENT OF COCAINE-INDUCED 5-HT DYSFUNCTION
    • 批准号:
      6846569
    • 项目类别:
    • 资助金额:
      $33.3万
    • 财政年份:
      2001
    • 负责人:
      GEORGE BATTAGLIA
    • 依托单位:
    PREPUBESCENT SSRIS & 5HT RECEPTOR SIGNALLING
    • 批准号:
      6625433
    • 项目类别:
    • 资助金额:
      $27.55万
    • 财政年份:
      1999
    • 负责人:
      GEORGE BATTAGLIA
    • 依托单位:
    海外基金